

Title:

Safety comparison of risk of liver dysfunction between generic and brand statin drugs marketed in Japan: a cohort study using MID-NET[®]

Journal name:

Therapeutic Innovation and Regulatory Sciences

Authors:

Hotaka Maruyama, Yuki Kinoshita, Takashi Ando, Jun Okui, Maki Komamine, Kazuhiro Kajiyama, Naoya Horiuchi, and Yoshiaki Uyama*

*** Correspondence:**

Yoshiaki Uyama

uyama-yoshiaki@pmda.go.jp

Center for Regulatory Science,

Pharmaceuticals and Medical Devices Agency,

Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan




Fig. S2 Risk of liver dysfunction by various statins on the secondary outcome (≥ CTCAE grade3)

*ATOR: atorvastatin, SIMV: simvastatin, PITA: pitavastatin, PRAV: pravastatin, FLUV: fluvastatin, ROSV: rosuvastatin

† cHR: crude hazard ratio, aHR: adjusted hazard ratio, Ref: reference

‡ Data are masked so that the number of patients (less than 10) cannot be identified according to the MID-NET® publication criteria.

§ The estimation accuracy of the adjusted hazard ratio was low for groups with a small number of patients